𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The role of both specific cellular adhesion and growth promotion in liver colonization by F9 embryonal carcinoma cells

✍ Scribed by Dario Rusciano; Patrizia Lorenzoni; Max M. Burger


Publisher
John Wiley and Sons
Year
1991
Tongue
French
Weight
816 KB
Volume
48
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Unselected F9 murine embryonal carcinoma cells preferentially colonize the liver upon injection into tail veins of syngeneic mice, while the lungs are only very rarely colonized. Here we show that F9 cells attach better to fibronectin than to laminin in an adhesion assay, like other liver‐colonizing cell lines. Moreover, assays of adhesion to extracellular matrix (ECM) prepared from rat organs (liver, lung and kidney) demonstrate that, in the absence of serum, F9 cells adhere better to liver‐than to kidney‐or lung‐derived ECM. Even in the presence of FCS, the adhesion to lung ECM remains very low. This very low adhesiveness of F9 cells to lung‐derived ECM correlates well with the finding that, in an organ distribution assay, tail‐vein‐injected F9 cells are very rapidly released from the lungs, when compared to the retention times of the lung‐specific murine melanoma cell line B16‐F10. Yet another property appears to contribute to organ‐specific colonization of these cells: extracts of liver promote the growth of F9 cells, in contrast to extracts of lung or kidney which have no effect. These data suggest that preferential formation of metastases in the liver following the intravenous injection of F9 cells is the result of both their adhesive abilities and their growth response to local microenvironment.


📜 SIMILAR VOLUMES


Tissue-specific growth suppression and c
✍ G W Xu; Z T Sun; K Forrester; X W Wang; J Coursen; C C Harris 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 646 KB

HCC patients are generally resistant to chemotherapy, Selective expression of cytotoxic gene products in tuwhich, in some cases, may be the result of a loss of function mor cells is one of the goals of gene therapy for treating mutation in the p53 gene. cancer. We are developing such a strategy for